Want to see AU:HMD full AI Analyst Report?
Top Page
HeraMED Ltd.
(Sydney:HMD)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.04
▲(5.00% Upside)
Action:Reiterated
Date:09/23/26
The score is held down primarily by weak financial performance—persistent operating losses and recurring cash burn—despite a cleaner balance sheet (zero debt) and improved gross margins. Technicals are relatively supportive with the price above key moving averages and positive MACD, but valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
Meaningful deleveraging has reduced the company’s dependence on debt financing and lowered interest-related pressure. A zero-debt position provides greater flexibility to manage operations and pursue its digital health strategy, although the modest equity base remains an important constraint.
Negative Factors
Revenue Contraction
Recent revenue contraction and a history of volatility weaken confidence in the company’s ability to consistently expand its customer base and commercial footprint. Without renewed top-line growth, fixed operating costs are harder to absorb and the improved gross margin is less likely to translate into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Meaningful deleveraging has reduced the company’s dependence on debt financing and lowered interest-related pressure. A zero-debt position provides greater flexibility to manage operations and pursue its digital health strategy, although the modest equity base remains an important constraint.
Read all positive factors
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$48.66M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-52.35%
EPS Growth40.38%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,151,055
30 Day Avg. Volume1,197,866
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europ...
HeraMED Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69K | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 95.42K | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.21M | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | -2.36M | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 0.00 | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 403.51K | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 1.75M | 621.27K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | ||||||
| Free Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 3.54M | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.04
Positive
Market Momentum
<0.01
Negative
53.90
Neutral
19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.90 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$45.57B | 20.97 | 23.88% | 1.02% | 4.74% | 4.44% | |
57 Neutral | AU$51.94M | 236.36 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$48.66M | -13.27 | -198.77% | ― | -52.35% | 40.38% | |
45 Neutral | AU$21.97M | -0.52 | -259.31% | ― | 14.85% | -1.74% | |
45 Neutral | AU$16.24M | -4.29 | -48.97% | ― | 40.65% | 45.45% | |
43 Neutral | AU$3.12M | -1.56 | -1788.57% | ― | -52.22% | 44.79% |
* Healthcare Sector Average
AU:HMD
HeraMED Ltd.
0.04
<0.01
7.69%
AU:CMP
Compumedics Limited
0.26
-0.04
-13.33%
AU:IPD
Impedimed Limited
0.01
-0.04
-72.00%
AU:UCM
Uscom Limited
0.01
0.00
0.00%
AU:AT1
Atomo Diagnostics Ltd.
0.02
-0.01
-40.00%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
31.79
-9.86
-23.67%
HeraMED Ltd. Corporate Events
HeraMED Secures Full-Scale Digital Maternity Rollout with US Health System Lee Health
Sep 15, 2026
Lee Health, a major non-profit healthcare system in Southwest Florida that delivers more than 8,000 babies annually, has approved the full commercial deployment of HeraMED’s digital maternity solution after a successful six-month pilot. The ...
HeraMED Shares Halted Ahead of Material Commercial Deployment News
Sep 14, 2026
HeraMED Ltd. has requested and received a trading halt on its ordinary shares from the ASX, with the suspension effective immediately and expected to last until either the start of normal trading on 17 September 2026 or the release of a pending an...
HeraMED Issues 3.3 Million Unquoted Performance Rights Under Incentive Plan
Sep 1, 2026
HeraMED Ltd. has notified the market of the issue of 3.3 million unquoted performance rights under its employee incentive scheme, dated 14 August 2026. The new awards, which are not intended to be quoted on the ASX, underscore the company’s ...
HeraMED Narrows Half-Year Loss as Revenue Slumps but Asset Backing Improves
Aug 28, 2026
HeraMED Limited reported a sharp contraction in revenue for the half-year ended 30 June 2026, with income from ordinary activities falling 72.5% to $38,325, while its net loss narrowed 29.2% to $1.6 million compared with the prior corresponding pe...
HeraMED strengthens ASX governance with new joint company secretary
Jul 31, 2026
HeraMED Limited has announced a change in its corporate governance structure, with Stephanie Vipond stepping down as Joint Company Secretary and Nova Taylor of Bio101 Financial Advisory appointed to the role alongside existing Joint Company Secret...
HeraMED Advances U.S. Digital Pregnancy Rollout with Lee Health and Philips
Jul 31, 2026
HeraMED reported that the June 2026 quarter was dominated by progress in U.S. commercialisation, centred on its partnership with Lee Health and ongoing negotiations with Philips for an expanded commercial agreement. The company highlighted that it...
HeraMED Director’s Options Lapse, Slightly Reducing Future Equity Exposure
Jul 24, 2026
HeraMED Ltd has reported a change in director Timothy Chapman’s relevant interests following the expiry and lapse of a tranche of unlisted options. Through Inverness Capital Pty Ltd as trustee of the Match Partner Investment Account, Chapman...
HeraMED Options Expire, Simplifying ASX-Listed Medtech’s Capital Structure
Jul 24, 2026
HeraMED Ltd has confirmed the expiry of 30,428,572 listed options (HMDAZ) with an exercise price of $0.12, which lapsed unexercised on 20 July 2026. The cessation of these options reduces the company’s pool of potential dilutive securities, ...
HeraMED Pilot with Lee Health Validates Digital-First Prenatal Care Model
Jul 13, 2026
HeraMED has completed Phase 1 of its Digital Pregnancy Journey pilot with U.S. provider Lee Health, testing the HeraCARE platform within a hybrid obstetrics model that blends virtual visits and remote monitoring. The six-month feasibility study, i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.